Senaparib hydrochloride | CAS# 1401683-39-3 | Biochemical

MedKoo Cat#: 576642 | Name: Senaparib hydrochloride

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Senaparib hydrochloride is a potent and selective oral PARP1/2 inhibitor with strong antitumor activity.

Chemical Structure

Senaparib hydrochloride

CAS#1401683-39-3 (HCl)

Theoretical Analysis

MedKoo Cat#: 576642

Name: Senaparib hydrochloride

CAS#: 1401683-39-3 (HCl)

Chemical Formula: C24H21ClF2N6O3

Exact Mass: 514.1332

Molecular Weight: 514.92

Elemental Analysis: C, 55.98; H, 4.11; Cl, 6.88; F, 7.38; N, 16.32; O, 9.32

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

1401683-39-3 (HCl) 1401682-78-7 (free base)

Synonym

IMP-4297 hydrochloride; IMP-4297 HCl; Senaparib hydrochloride; Senaparib HCl

IUPAC/Chemical Name

2,4(1H,3H)-Quinazolinedione, 5-fluoro-1-((4-fluoro-3-((4-(2-pyrimidinyl)-1-piperazinyl)carbonyl)phenyl)methyl)-, hydrochloride (1:1)

InChi Key

IBDAAVBRRAWCKS-UHFFFAOYSA-N

InChi Code

1S/C24H20F2N6O3.ClH/c25-17-6-5-15(14-32-19-4-1-3-18(26)20(19)21(33)29-24(32)35)13-16(17)22(34)30-9-11-31(12-10-30)23-27-7-2-8-28-23;/h1-8,13H,9-12,14H2,(H,29,33,35);1H

SMILES Code

Cl.Fc1ccc(CN2C(=O)NC(=O)c3c(F)cccc23)cc1C(=O)N4CCN(CC4)c5ncccn5

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 514.92 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Wu X, Liu J, Wang J, Wang L, Lin Z, Wang X, Zhu J, Kong B, Fei J, Tang Y, Xia B, Liang Z, Wang K, Huang Y, Zheng H, Lin A, Jiang K, Wang W, Wang X, Lou G, Pan H, Yao S, Li G, Hao M, Cai Y, Chen X, Yang Z, Chen Y, Wen H, Qu P, Xu C, Hsieh CY; FLAMES Investigators. Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial. Nat Med. 2024 Jun;30(6):1612-1621. doi: 10.1038/s41591-024-03003-9. Epub 2024 May 15. PMID: 38750351. 2: Cai SX, Ma N, Wang X, Guo M, Jiang Y, Tian YE. The Discovery of a Potent PARP1 Inhibitor Senaparib. Mol Cancer Ther. 2025 Jan 2;24(1):47-55. doi: 10.1158/1535-7163.MCT-23-0625. PMID: 38920409. 3: Meng X, Lin X, Jiang R, Lu Y, Zeng L, Cao M, Zhang J. Effect of Food on the Pharmacokinetics of Senaparib (IMP4297) in Healthy Chinese Subjects. Clin Drug Investig. 2022 Nov;42(11):1009-1016. doi: 10.1007/s40261-022-01198-8. Epub 2022 Oct 14. PMID: 36239914; PMCID: PMC9617823. 4: Gao B, Voskoboynik M, Cooper A, Wilkinson K, Hoon S, Hsieh CY, Cai S, Tian YE, Bao J, Ma N, Wang C, Zhang M, Li B, Guo M, Zhou R, Wang X, Xu C, de Souza P. A phase 1 dose-escalation study of the poly(ADP-ribose) polymerase inhibitor senaparib in Australian patients with advanced solid tumors. Cancer. 2023 Apr 1;129(7):1041-1050. doi: 10.1002/cncr.34662. Epub 2023 Jan 31. PMID: 36718624. 5: Hu X, Hsieh CY, Zhang Y, Liu W, Xu S, Cai SX, Liu L, Zhang M, Shi H, Zhang H, Liu P, Li X, Xu P. Effect of a strong CYP3A4 inhibitor and inducer on the pharmacokinetics of senaparib (IMP4297) in healthy volunteers: A drug-drug interaction study. Br J Clin Pharmacol. 2023 Jun;89(6):1767-1779. doi: 10.1111/bcp.15624. Epub 2023 Jan 3. PMID: 36458825. 6: Cao J, Guo H, Ji D, Shen W, Zhang S, Hsieh CY, Xiong Cai S, Edward Tian Y, Xu C, Zhang P, Xu B. Safety, Tolerability, and Pharmacokinetics of Senaparib, a Novel PARP1/2 Inhibitor, in Chinese Patients With Advanced Solid Tumors: A Phase I Trial. Oncologist. 2023 Dec 11;28(12):e1259-e1267. doi: 10.1093/oncolo/oyad163. PMID: 37338150; PMCID: PMC10712727.